Clinical data for cabozantinib to be presented at ASCO annual meeting

Clinical data for cabozantinib to be presented at ASCO annual meeting

News and Articles
Apr 2 2012

Exelixis, Inc. (NASDAQ:EXEL) announced today that its lead compound, cabozantinib, will be the subject of nine separate data presentations at the upcoming Annual Meeting of the American Society of Clinical Oncology (ASCO). The meeting will be held June 1-5, 2012, in Chicago, Illinois. Clinical data for cabozantinib will be featured in four oral presentations, four poster discussion presentations, and one general poster presentation. For the first time, investigators will present data from EXAM, the pivotal trial of cabozantinib in medullary thyroid cancer. Initial positive top-line results from EXAM were announced in October 2011.    

“The nine data presentations at this year’s ASCO Annual Meeting are indicative of the growing depth and breadth of cabozantinib’s global clinical development program,” said Michael M. Morrissey, Ph.D., president and chief executive officer of Exelixis. “As the data across multiple tumor types for cabozantinib continues to mature, its unique activity profile is increasingly being recognized broadly across the oncology community. We look forward to sharing these exciting data at ASCO later this year.”

The full roster of cabozantinib data presentations expected at the meeting (all times Central Daylight Time):

Oral Presentations

  • “Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT)” (Abstract #4006)

    Dr. Chris Verslype, Hepatology, University Hospitals Gasthuisberg, Belgium

    Oral Abstract Session: Gastrointestinal (Noncolorectal) Cancer

    Saturday, June 2; 3:00 p.m. – 6:00 p.m.

  • “Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC)” (Abstract #4504)

    Dr. Toni K. Choueiri, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute/Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

    Oral Abstract Session: Genitourinary Cancer (Nonprostate)

    Saturday, June 2; 3:00 p.m. – 6:00 p.m.

  • “An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline” (Abstract #5508)

    Dr. Patrick Schöffski, Department of General Medical Oncology, Catholic University Leuven, Belgium

    Clinical Science Symposium: Targeting Therapeutics for Thyroid Cancers

    Monday, June 4; 11:30 a.m. – 1:00 p.m.

  • “Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE)” (Abstract #4513)

    Dr. Matthew R. Smith, Massachusetts General Hospital Cancer Center, Boston, MA

    Oral Abstract Session: Genitourinary Cancer (Prostate)

    Tuesday, June 5; 9:45 a.m. – 12:45 p.m.

Poster Discussion Presentations

  • “Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT)” (Abstract #535)

    Dr. Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA

    Poster Discussion Session: Breast Cancer-HER2/ER

    Saturday, June 2; 1:15 p.m. – 5:45 p.m.

  • “Activity of cabozantinib (XL184) in metastatic melanoma: Results from a phase II randomized discontinuation trial (RDT)” (Abstract #8531)

    Dr. Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ

    Poster Discussion Session: Melanoma/Skin Cancers

    Saturday, June 2; 1:15 p.m. – 5:45 p.m.

  • “Investigator sponsored trial of efficacy and tolerability of cabozantinib (cabo) at lower dose: A dose-finding study in men with castration-resistant prostate cancer (CRPC) and bone metastases” (Abstract #4566)

    Dr. Richard J. Lee, Massachusetts General Hospital Cancer Center, Boston, MA

    Poster Discussion Session: Genitourinary (Prostate) Cancer

    Monday, June 4, 8:00 a.m. – 12:30 p.m.

  • “Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a phase II randomized discontinuation trial (RDT)” (Abstract #7514)

    Dr. Beth A. Hellerstedt, US Oncology Research, LLC, McKesson Specialty Health, The Woodlands, TX, and Texas Oncology, Central Austin Cancer Center, Austin, TX

    Poster Discussion Session: Lung Cancer – Non-small Cell Metastatic

    Tuesday, June 5; 8:00 a.m. – 12:30 p.m.

Poster Presentation

  • “Antitumor activity of cabozantinib (XL184) in a cohort of patients (pts) with differentiated thyroid cancer (DTC)” (Abstract #5547)

    Dr. Maria E. Cabanillas, University of Texas M. D. Anderson Cancer Center, Houston, TX

    General Poster Session: Head and Neck Cancer

    Saturday, June 2; 1:15 p.m. – 5:15 p.m.

Source: Exelixis, Inc.

Source: www.news-medical.net

Rate article
Add a comment